Q Therapeutics, Inc. is organizeda rounf development of glial cell-based therapeutic products for central nervous system (CNS) disorders in which a disease or injury inhibits normal myelin growth and enzyme performance. The direct source of more than 90% of cells in the mammalian nervous system Glial cells are essential for maintaining its normal functions. Insufficient or defective myelin and/or enzyme function is responsible disorders such as multiple sclerosis, cerebral palsy, leukodystrophies, and certain lysosomal storage disorders and prevents recovery from white-matter stroke and spinal cord injury. Q Therapeuticsâ technologies allow for GMP scale-up and treatment of large population disorders while holding the promise of restorative, not just preventive, therapy for these CNS conditions. Products currently under development are targeted to treat multiple sclerosis (MS), transverse myelitis, ALS (Lou Gehrig's Disease), cerebral palsy, spinal cord injury, traumatic brain injury, stroke, Parkinson's Disease and Alzheimer's Disease. In Spring 2018, the firm formed a Joint Venture with REPROCELL Inc., Japanâs first induced pluripotent stem cell (iPSC) company,. Designated MAGiQ Therapeutics, Inc., a Japanese joint venture company. MAGiQ will develop iPSC-derived, glial-restricted progenitor cells (GRPs), in collaboration with Q Therapeutics and REPROCELL, to treat demyelinating and degenerative diseases of the C
